Oragenics (OGEN) Sees Unusually-High Trading Volume

Oragenics Inc (NYSEAMERICAN:OGEN) saw unusually-high trading volume on Monday . Approximately 4,630,556 shares changed hands during mid-day trading, an increase of 210% from the previous session’s volume of 1,495,099 shares.The stock last traded at $0.55 and had previously closed at $0.47.

Separately, HC Wainwright started coverage on shares of Oragenics in a research note on Friday, April 26th. They set a “buy” rating and a $2.00 price target on the stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC grew its holdings in Oragenics by 95.9% during the 4th quarter. Barclays PLC now owns 135,400 shares of the biotechnology company’s stock worth $116,000 after acquiring an additional 66,275 shares in the last quarter. Virtu Financial LLC grew its holdings in Oragenics by 297.9% during the 4th quarter. Virtu Financial LLC now owns 138,233 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 103,496 shares in the last quarter. Sabby Management LLC acquired a new position in Oragenics during the 1st quarter worth $299,000. BlackRock Inc. grew its holdings in Oragenics by 82,549.2% during the 4th quarter. BlackRock Inc. now owns 705,824 shares of the biotechnology company’s stock worth $606,000 after acquiring an additional 704,970 shares in the last quarter. Finally, Harvest Capital Strategies LLC acquired a new position in Oragenics during the 1st quarter worth $780,000.

COPYRIGHT VIOLATION NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.com-unik.info/2019/05/20/oragenics-ogen-sees-unusually-high-trading-volume.html.

About Oragenics (NYSEAMERICAN:OGEN)

Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.

Recommended Story: Market Capitalization – What it Means for Investors

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit